[Antitumor activity of the lysates prepared from anti-CD3 antibody activated killer cells]

This study was directed at the antitumor activity of the lysates prepared from CD3McAb activated killer cells. We separated the peripheral blood monocytes(PBMC) from normal adults. The PBMC were induced by monoclonal antibody specific for CD3(CD3McAb) and activated by rIL-2. The CD3McAb-activated killer cells (CD3AK) were smashed by ultrasonic wave, along with frozen and thawed three times, then the lysates were obtained by centrifugation. The lysates were tested for antitumor activity in vivo and in vitro. The results revealed that the inhibition rate of the lysates that acted on mice solid tumor hepatoma 22(H22) was 68.20% and the killing activity of the lysates on K562 and Raji were 83.32%, and 66.83% respectively. The results of this experiment suggested that the lysates prepared from CD3McAb-activated killer cells is one of probable agents that might apply to biotherapy for tumors.